P ckit ALLO1
Alternative Names: Anti-cKit CAR-T therapy - Poseida Therapeutics; P-ckit-ALLO1Latest Information Update: 17 May 2021
At a glance
- Originator Poseida Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 11 May 2021 Pharmacodynamics data from preclinical studies in Acute myeloid leukaemia released by Poseida Therapeutics
- 03 Mar 2021 Anti cKit CAR-T therapy - Poseida Therapeutics is available for licensing as of 03 Mar 2021. https://poseida.com/
- 24 Feb 2021 Preclinical trials in Acute myeloid leukaemia in USA (Parenteral)